Sacituzumab Govitecan plus Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study

被引：0
|
作者：
Patel, Jyoti [1 ]
Cho, Byoung Chul [2 ]
Dols, Manuel Cobo [3 ]
Cabanillas, Roxanna Reyes [4 ]
Baz, David Vicente [5 ]
Pradera, Jose Fuentes [6 ]
Grisanti, Salvatore [7 ]
Gabayan, Afshin E. [8 ]
Lee, Ki Hyeong [9 ]
Cho, Eun Kyung [10 ]
Mekan, Sabeen Fatima [11 ]
Safavi, Farnoush [11 ]
Fernando, Nalumka [11 ]
Chisamore, Michael J. [12 ]
Recki, Martin [13 ]
机构：
[1] Robert H Lurie Comprehens Canc Ctr, Northwestern Med, Chicago, IL USA
[2] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[3] Reg & Virgen Victoria Univ Hosp, IBIMA, Malaga, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hosp Univ Virgen Macarena, Seville, Spain
[6] Hosp Univ Virgen Valme, Seville, Spain
[7] ASST Spedali Civili Brescia, Brescia, Italy
[8] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[9] Chungbuk Natl Univ Hosp, Cheongju, Chungbuk, South Korea
[10] Gachon Univ, Gil Med Ctr, Incheon, South Korea
[11] Gilead Sci Inc, Foster City, CA USA
[12] Merck & Co Inc, Rahway, NJ USA
[13] German Ctr Lung Res DZL, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PPD01.06
引用
收藏
页码：E6 / E7
页数：2
相关论文
共 50 条
  • [1] Sacituzumab Govitecan plus Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
    Cho, B. C.
    Dols, M. C.
    Cabanillas, R. Reyes
    Baz, D. Vicente
    Pradera, J. Fuentes
    Grisanti, S.
    Gabayan, A. E.
    Lee, K. H.
    Cho, E. K.
    Mekan, S.
    Safavi, F.
    Fernando, N.
    Chisamore, M. J.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S54 - S54
  • [2] Sacituzumab govitecan (SG) plus pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02
    Patel, Jyoti D.
    Cho, Byoung Chul
    Cobo, Manuel
    Cabanillas, Roxana Reyes
    Vicente, David
    Pradera, Jose Fuentes
    Garon, Edward B.
    Mok, Tony S. K.
    Cappuzzo, Federico
    Neal, Joel W.
    Mekan, Sabeen Fatima
    Safavi, Farnoush
    Fernando, Nelumka
    Chisamore, Michael Jon
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC).
    Garon, Edward B.
    Liu, Stephen V.
    Owen, Scott Peter
    Reck, Martin
    Neal, Joel W.
    Vicente, David
    Mekan, Sabeen Fatima
    Safavi, Farnoush
    Fernando, Nelumka
    Mok, Tony S. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
    Paz-Ares, Luis G.
    Juan-Vidal, Oscar
    Mountzios, Giannis S.
    Felip, Enriqueta
    Reinmuth, Niels
    de Marinis, Filippo
    Girard, Nicolas
    Patel, Vipul M.
    Takahama, Takayuki
    Owen, Scott P.
    Reznick, Douglas M.
    Badin, Firas B.
    Cicin, Irfan
    Mekan, Sabeen
    Patel, Riddhi
    Zhang, Eric
    Karumanchi, Divyadeep
    Garassino, Marina Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24)
  • [5] Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
    Gray, Jhanelle E.
    Saltos, Andreas
    Tanvetyanon, Tawee
    Haura, Eric B.
    Creelan, Ben
    Antonia, Scott J.
    Shafique, Michael
    Zheng, Hong
    Dai, Wenjie
    Saller, James J.
    Chen, Zhihua
    Tchekmedyian, Nishan
    Goas, Kristen
    Thapa, Ram
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Beg, Amer A.
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6623 - 6632
  • [6] Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study
    Moskovitz, Mor
    Okamoto, Isamu
    Chen, Peng
    Patel, Jilpa
    Mekan, Sabeen
    Pietanza, M. Catherine
    Zhu, Yalin
    Eiras, Renata
    Tiseo, Marcello
    CANCER RESEARCH, 2023, 83 (08)
  • [7] Phase 1 Study of Pembrolizumab and Stereotactic or Hypofractionated Radiation for Metastatic Non-small Cell Lung Cancer
    Tang, C.
    de Groot, P.
    Hess, K.
    Shabaan, S.
    Gomez, D. R.
    Chang, J. Y.
    Lin, S. H.
    Paraskevopoulos, T.
    Raju, U.
    Simon, G. R.
    Papadimitrakopoulou, V.
    Liao, Z.
    Fossella, F. V.
    Glisson, B. S.
    Komaki, R. U.
    Hahn, S. M.
    Heymach, J.
    Welsh, J. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S160 - S161
  • [8] Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).
    Xu, Nong
    Ying, Kejing
    Wang, Ziping
    Liu, Yunpeng
    Jiang, Haiping
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [10] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
    Gandhi, L.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Vida, J.
    Wei, Z.
    Yang, J.
    Raftopoulos, H.
    Pietanza, M. C.
    Garassino, M. C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22): : 2078 - 2092
12345